Clinical Trial Update: Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports safety and pharmacology results for atezolizumab alone and with BCG in high-risk non-muscle-invasive bladder cancer (NMIBC); …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• BCG (Bacillus Calmette-Guérin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Bladder Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-10-28